Now Playing
Opinion|Videos|June 25, 2024
Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5